Sight Sciences, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 12, 2024. Although the request references 2023 Q4, this is an annual filing. The supplied text does not provide a clear standalone fourth-quarter income statement or cash-flow values.
Business context
Sight Sciences develops and sells ophthalmic medical devices through two segments: Surgical Glaucoma, principally OMNI and SION, and Dry Eye, principally TearCare. Surgical Glaucoma generated 91.7% of FY2023 revenue. Most revenue was from U.S. customers. The company relies on third-party manufacturers and emphasizes clinical evidence, physician training, adoption, and reimbursement access.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Revenue | $81.1 million | $71.3 million | +13.6% |
| Gross profit | $69.2 million | $59.0 million | +17.3% |
| Gross margin | 85.3% | 82.7% | +2.6 percentage points |
| Operating expenses | $126.4 million | $142.9 million | −11.5% |
| Operating loss | $57.3 million | $84.0 million | Loss narrowed |
| Net loss | $55.5 million | $86.2 million | Loss narrowed |
| Net loss per share, basic and diluted | $1.14 | $1.80 | Loss per share narrowed |
| Cash used in operating activities | $47.2 million | $76.0 million | Use decreased |
Surgical Glaucoma revenue rose 13.3% to $74.3 million, with segment gross margin of 88.1% versus 87.4%. Dry Eye revenue rose 17.6% to $6.7 million, and segment gross margin improved to 54.8% from 29.1%. Management attributed growth to more units sold and greater facility utilization in Surgical Glaucoma, and more TearCare procedures in Dry Eye. The Dry Eye margin increase included the comparison effect of 2022 charges related to the SmartHub 1.0 recall.
R&D expense declined 23.2% to $17.6 million, and SG&A declined 9.3% to $108.9 million. Interest expense increased to $5.4 million from $4.5 million; other income increased to $7.2 million, primarily due to income from treasury investments. The company remained loss-making and reported an accumulated deficit of $294.8 million.
At December 31, 2023, cash and cash equivalents were $138.1 million, down from $185.0 million a year earlier. Current assets were $162.9 million and current liabilities $12.3 million. Year-end debt principal was $35.0 million. In January 2024, the company refinanced the prior loan with a $35.0 million initial draw under a senior secured facility of up to $65.0 million; additional draws are conditional. The new facility carries an initial floating rate of 10.85%, is secured by substantially all assets, and includes minimum cash and revenue covenants. Management expects available cash and potential facility borrowings to fund operations for at least 12 months, subject to assumptions including continued adequate OMNI reimbursement.
Material changes and notable developments
- Total revenue increased 13.6%, while operating expenses fell 11.5%; annual net loss narrowed by $30.7 million.
- In June 2023, five Medicare Administrative Contractors (MACs) proposed draft coverage determinations that could have treated certain MIGS procedures associated with OMNI as investigational and non-covered. The amended determinations were published as final with a future effective date, then withdrawn in late December before taking effect. The affected states represented about 63% of 2022 Surgical Glaucoma revenue.
- Management said fourth-quarter demand was softer amid uncertainty from the draft coverage determinations. The company also disclosed a reduction in full-year 2023 revenue guidance in September; the supplied filing text does not state the prior and revised guidance figures.
- In October 2023, the company began a strategic realignment that included an approximately 10% workforce reduction, intended to lower expenses and extend cash runway.
- The FDA cleared next-generation versions of OMNI and TearCare in 2023; neither had been launched by year-end. OMNI received EU MDR approval in December 2023. The company reported UKCA certification for OMNI in March 2024.
- The company reported completion of Phase 1 of the SAHARA TearCare trial, with results showing superiority to Restasis on the primary TBUT endpoint and non-inferiority on OSDI at six months. Further follow-up and publication were planned.
- Management reported that a previously identified material weakness in financial reporting controls was remediated as of December 31, 2023. The independent auditor did not attest to internal control effectiveness because the company is an emerging growth company.
Outlook, risks, and contingencies
The company did not provide quantified FY2024 revenue or earnings guidance in the supplied filing text. Management expects continued losses for at least the next several years while investing in clinical studies, commercial capabilities, market access, and product development, alongside efforts to control spending and improve efficiency. The company is focused on expanding OMNI use, developing standalone MIGS, and improving TearCare reimbursement and access.
- Reimbursement: Future Medicare or commercial payer restrictions could materially affect OMNI and SION adoption. TearCare has no formal Medicare or private-payer coverage policy and is largely patient-pay.
- Profitability and cash burn: Continued losses, operating cash outflows, and reliance on assumptions about revenue and reimbursement could require additional financing or spending changes.
- Debt: The new secured loan has a high floating rate, covenants, and conditional additional tranches; failure to comply could limit access to funds or trigger default remedies.
- Execution and adoption: Results depend on physician and patient adoption, clinical evidence, training, sales execution, and the success of cost-reduction initiatives.
- Supply chain: The company has no manufacturing facilities and relies on a limited number of third-party suppliers, including a key manufacturer in China.
- Litigation: Sight Sciences’ patent-infringement action against Ivantis and Alcon remained unresolved at filing; a jury trial was scheduled for the first half of April 2024. The company said it could not predict the outcome or estimate the potential financial impact.
- Other risks: Competition, evolving medical-device regulation, product liability, cybersecurity, and the durability of clinical outcomes could affect results. The company also disclosed investigations announced by plaintiff law firms after its September 2023 guidance reduction; whether they would lead to litigation was uncertain.
Important facts for investors to verify
- Current Medicare and commercial coverage for OMNI/SION, and whether any new or revised MAC determinations have emerged since the filing.
- Actual FY2024 revenue outlook and whether fourth-quarter 2023 performance changed the company’s demand assumptions.
- Cash runway, operating cash use, covenant compliance, interest cost, and availability of conditional borrowings under the Hercules facility.
- Progress toward TearCare reimbursement and adoption, including later SAHARA follow-up results and publication.
- Commercial launch timing and revenue contribution of next-generation OMNI and TearCare products.
- Outcome and financial consequences, if any, of the patent litigation with Ivantis and Alcon and any securities-related proceedings.
- Whether the workforce realignment achieves planned savings without impairing commercial execution or product development.